USD
+$0.00
(+0.00%
)At Close (As of Oct 14, 2025)
$1.23B
Market Cap
-
P/E Ratio
-0.66
EPS
$10.95
52 Week High
$3.30
52 Week Low
HEALTHCARE
Sector
Field | Value (EUR) |
---|---|
Gross Profit | $156M |
Total Revenue | $156M |
Cost Of Revenue | $148M |
Costof Goods And Services Sold | $148M |
Operating Income | -$39M |
Selling General And Administrative | $46M |
Research And Development | $148M |
Operating Expenses | $194M |
Investment Income Net | - |
Net Interest Income | $24M |
Interest Income | $25M |
Interest Expense | $886K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $12M |
Income Before Tax | $21M |
Income Tax Expense | $6.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $15M |
Comprehensive Income Net Of Tax | - |
Ebit | $22M |
Ebitda | $34M |
Net Income | $15M |
Field | Value (EUR) |
---|---|
Total Assets | $696M |
Total Current Assets | $630M |
Cash And Cash Equivalents At Carrying Value | $237M |
Cash And Short Term Investments | $237M |
Inventory | - |
Current Net Receivables | $6.7M |
Total Non Current Assets | $67M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $1.6M |
Intangible Assets Excluding Goodwill | $1.6M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $368M |
Other Current Assets | $18M |
Other Non Current Assets | - |
Total Liabilities | $121M |
Total Current Liabilities | $68M |
Current Accounts Payable | $10M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.9M |
Total Non Current Liabilities | $53M |
Capital Lease Obligations | $16M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $16M |
Other Current Liabilities | $15M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $575M |
Treasury Stock | - |
Retained Earnings | -$590M |
Common Stock | $1.2M |
Common Stock Shares Outstanding | $107M |
Field | Value (EUR) |
---|---|
Operating Cashflow | -$158M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $12M |
Capital Expenditures | $16M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$152M |
Cashflow From Financing | $320M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $15M |
Field | Value (EUR) |
---|---|
Gross Profit | $156M |
Total Revenue | $156M |
Cost Of Revenue | $148M |
Costof Goods And Services Sold | $148M |
Operating Income | -$39M |
Selling General And Administrative | $46M |
Research And Development | $148M |
Operating Expenses | $194M |
Investment Income Net | - |
Net Interest Income | $24M |
Interest Income | $25M |
Interest Expense | $886K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $12M |
Income Before Tax | $21M |
Income Tax Expense | $6.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $15M |
Comprehensive Income Net Of Tax | - |
Ebit | $22M |
Ebitda | $34M |
Net Income | $15M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Immatics NV is a leading clinical-stage biopharmaceutical company, headquartered in Tübingen, Germany, specializing in the discovery and development of innovative T-cell receptor (TCR) based immunotherapies for cancer treatment. The company leverages its proprietary platform to identify and target cancer-specific antigens, aiming to enhance the efficacy of immune responses against tumors. With a strong pipeline of therapeutic candidates, Immatics is poised to address significant unmet needs in oncology, making it a compelling opportunity for institutional investors interested in cutting-edge cancer therapies.